8-K: Surrozen Reports 2025 Results, Advances Pipeline, Secures $5M Milestone

Surrozen, Inc. announced its full-year 2025 financial results, highlighted by pipeline advancements, a $5 million milestone payment from Boehringer Ingelheim, and a significant increase in net loss.

Summary

• Reported financial results for the fourth quarter and full year ended December 31, 2025.
• Received a $5.0 million milestone payment from Boehringer Ingelheim for SZN-413 due to a positive outcome in an IND-enabling GLP toxicology study.
• Remains on track to submit an Investigational New Drug (IND) application for SZN-8141 in the second half of 2026.
• Cash and cash equivalents increased to $89.2 million as of December 31, 2025, from $34.6 million as of December 31, 2024.
• Net proceeds of $26.9 million from at-the-market common stock sales in January 2026 and $3.3 million from warrant exercises in February and March 2026 further bolstered cash.
• Total revenue for 2025 was $3.477 million, down from $10.655 million in 2024, primarily due to no collaboration revenue in 2025 compared to $10.0 million in 2024.
• Research and Development (R&D) expenses increased to $29.365 million in 2025 from $21.132 million in 2024, driven by ophthalmology programs.
• General and Administrative (G&A) expenses increased to $16.204 million in 2025 from $15.062 million in 2024.
• Net loss significantly widened to $242.026 million, or ($32.37) per share, for 2025, compared to $63.564 million, or ($21.67) per share, for 2024. This was largely due to non-cash losses related to the 2025 PIPE and changes in fair value of tranche liability and warrant liabilities.
• Strengthened strategic leadership in 2025 by forming a Clinical Advisory Board and appointing Daniel Chao, M.D., Ph.D., as VP and Head of Clinical Development, and Andrew Maleki as CFO.
• Plans to present retinal vascular research on SZN-8141 at the 2026 ARVO Annual Meeting on May 4, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While pipeline progress and a milestone payment are positive, the substantial increase in net loss, driven by non-cash financing-related losses, and a decline in total revenue present significant financial headwinds.

Positives

• Received a $5.0 million milestone payment from Boehringer Ingelheim for SZN-413, indicating positive preclinical progress.
• Cash and cash equivalents significantly increased to $89.2 million by December 31, 2025, from $34.6 million at the end of 2024.
• Further strengthened cash position with $26.9 million from common stock sales in January 2026 and $3.3 million from warrant exercises in February and March 2026.
• Lead candidate SZN-8141 remains on track for IND submission in the second half of 2026.
• Strengthened leadership team and ophthalmology expertise in 2025 with key appointments and a Clinical Advisory Board.
• Preclinical data for SZN-8141 and SZN-8143 demonstrated Wnt signaling activation, normal retinal vessel regrowth, and suppression of pathological vessel growth.

Negatives

• Net loss significantly widened to $242.026 million in 2025 from $63.564 million in 2024, primarily due to substantial non-cash losses.
• Total revenue decreased to $3.477 million in 2025 from $10.655 million in 2024, mainly due to the absence of collaboration revenue in 2025 (compared to $10.0 million in 2024).
• Research and Development (R&D) expenses increased to $29.365 million in 2025 from $21.132 million in 2024.
• General and Administrative (G&A) expenses increased to $16.204 million in 2025 from $15.062 million in 2024.
• Significant non-cash losses recorded in 2025: $71.084 million loss on execution of the 2025 PIPE, $104.847 million loss on change in fair value of tranche liability, and $26.312 million other expense, net (primarily non-cash change in fair value of warrant liabilities).
• Collaboration with TCGFB, Inc. for TGFantibodies research was terminated in November 2025.

Risks

• Uncertainty regarding the initiation, cost, timing, progress, and results of research and development activities, preclinical and clinical trials for product candidates.
• Ability to fund preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising.
• Ability to identify, develop, and commercialize drug candidates successfully.
• Ability to successfully complete preclinical and clinical studies for product candidates.
• Effects arising from volatility in global economic, political, regulatory, and market conditions.
• Additional unknown or currently immaterial risks that could cause actual results to differ materially from forward-looking statements.

Future Outlook

Surrozen expects to submit an Investigational New Drug (IND) application for SZN-8141 to the FDA in the second half of 2026. The company anticipates potential future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales from its partnership with Boehringer Ingelheim for SZN-413.

Management Comments

• "2025 was a year of significant momentum as we progressed two lead product candidates in retinal vascular disease, advanced our platform for developing multifunctional biologic candidates that selectively activate Wnt signaling in combination with other key disease pathways and further strengthened our management team to drive our long-term growth strategy." Craig Parker, President and Chief Executive Officer of Surrozen.
• "2026 is an exciting year for us as we expect to submit an IND application for SZN-8141 in the second half of the year and continue our focus on developing therapeutics that address critical unmet needs in retinal diseases." Craig Parker, President and Chief Executive Officer of Surrozen.

Industry Context

StockSavvy.ai notes that Surrozen operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on ophthalmology therapeutics. The Wnt signaling pathway is a promising area for drug development, and the company's dual-pathway approach (Wnt agonism with VEGF/IL-6 antagonism) for retinal diseases like DME and wet AMD aims to differentiate its candidates from existing anti-VEGF monotherapies and dual-pathway agents. The $5 million milestone payment from Boehringer Ingelheim validates its Wnt-modulating technology and partnership strategy, a common approach for smaller biotechs to de-risk and fund development. The significant increase in net loss, largely due to non-cash items related to financing activities, is not uncommon for early-stage biotech companies heavily investing in R&D and relying on capital raises.

Comparison to Industry Standards

• The milestone payment from Boehringer Ingelheim for SZN-413, following a positive IND-enabling GLP toxicology study, is a positive indicator of preclinical progress, comparable to similar early-stage licensing deals in the biotech industry. For example, companies like Regeneron and Novartis frequently engage in such collaborations for novel drug candidates.
• The planned IND submission for SZN-8141 in the second half of 2026 aligns with typical timelines for preclinical drug development in ophthalmology, where candidates like those from Apellis Pharmaceuticals or Iveric Bio have progressed through similar stages.
• The substantial net loss of $242.026 million, while high, is largely driven by non-cash accounting adjustments related to complex financing structures (PIPEs, warrants, tranche liabilities), which are common in the biotech funding landscape. This is not directly comparable to the operational losses of mature, revenue-generating pharmaceutical companies but is typical for development-stage biotechs like those seen in the early phases of companies such as Kodiak Sciences or EyePoint Pharmaceuticals, which require significant capital for R&D.
• The cash position of $89.2 million, bolstered by recent capital raises, provides a runway for continued operations, which is a critical metric for biotech companies, often compared to their burn rate.

Management Changes

Corporate Governance

Related Party Transactions

• Research service revenue from a related party was $3.477 million for the year ended December 31, 2025, compared to $0.655 million for the same period in 2024, driven by the collaboration with TCGFB, Inc. for TGFantibodies research.
• The collaboration with TCGFB, Inc. was terminated in November 2025.

Stakeholder Impact

• Shareholders: Potential for dilution from at-the-market stock sales and warrant exercises. Significant non-cash losses related to financing activities could impact perceived value. Pipeline progress and milestone payments offer future upside potential.
• Employees: Strengthening of leadership roles indicates continued investment in key personnel.
• Customers (future patients): Continued development of SZN-8141 and SZN-8143 offers hope for new treatments for sight-threatening ophthalmic conditions.
• Partners (Boehringer Ingelheim): Achievement of a research milestone for SZN-413 strengthens the partnership and validates Surrozen's technology.
• Creditors: The increased cash position provides a stronger short-term liquidity profile, but the substantial net loss and reliance on capital raises indicate ongoing financial needs.

Next Steps

• Submit an Investigational New Drug (IND) application for SZN-8141 to the FDA in the second half of 2026.
• Present retinal vascular research on SZN-8141 at the 2026 ARVO Annual Meeting on May 4, 2026.
• Continue developing therapeutics for critical unmet needs in retinal diseases.
• Boehringer Ingelheim to continue development of SZN-413, potentially triggering future milestone payments and royalties.

Key Dates

Recommendation

While Surrozen achieved a significant development milestone payment and advanced its lead pipeline candidates, the substantial increase in net loss, primarily due to non-cash financing-related charges, and a decline in collaboration revenue present considerable financial challenges. The company's cash position has improved with recent capital raises, providing a runway for operations, but the underlying operational losses remain high. Investors should hold to monitor the progress of SZN-8141 towards IND submission and subsequent clinical development, as well as the company's ability to manage its burn rate and secure future funding without excessive dilution. The long-term potential in Wnt-based ophthalmology therapeutics is promising, but the financial performance indicates a high-risk, high-reward profile typical of early-stage biotech.

Keywords

Biotechnology, Wnt signaling, Ophthalmology, Retinal diseases, SZN-8141, SZN-8143, SZN-413, IND application, Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (wet AMD), Boehringer Ingelheim, Clinical trials, Drug development, Financial results, SEC filing, SRZN